This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

St. Jude's Growth Is Looking Sickly

Stocks in this article: STJJNJMDTBSX

NEW YORK ( TheStreet) -- There isn't much a company can do when investors have fallen in love with their stock. Shares of St. Jude Medical (STJ) have soared close to 40% over the past six months, management has done nothing to taper the optimism. This is a good thing. But I don't see where there's meaningful value left for new investors.

The good news is that the company continues to make progress and has moved on from prior controversy over its Riata leads. You can argue that the depths from which St. Jude has emerged is enough to believe the worst is over. That may be so.

My problem is that growth has sputtered. At best, the recent results have not justified the valuation. And with better bargains out there such as Johnson & Johnson (JNJ) and Medtronic (MDT), St. Jude's execution has to be perfect over the next several quarters to sustain this level.

With fourth-quarter revenue advancing roughly 4% year over year, I've developed doubts about St. Jude's clinical pipeline. Given that the company just reported (in my opinion) its fifth consecutive so-so quarter, I worry that investors are showing too much patience waiting on St. Jude to produce the sort of returns the valuation presumes.

In fairness, there wasn't anything to be surprised about in St. Jude's earnings report. In most cases, that would be a good thing. But investors aren't paying for non-events. Not at almost twice the multiple of Medtronic.

As I've said, though, the company is making progress. The 6% year over year growth in its Cardiac Rhythm Management was one notable example. I was equally pleased (even stunned) to see the 7% jump in the implantable cardioverter defibrillators  business.

If you recall, in the October quarter the ICD segment grew at just 3%. And there were concerns that St. Jude was bleeding market share to Medtronic and Boston Scientific (BSX). Truth be told, I was one of those critics. But I can't say that I feel the same way today.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs